ATE348112T1 - Krebserkrankungen modifizierende antikörper - Google Patents

Krebserkrankungen modifizierende antikörper

Info

Publication number
ATE348112T1
ATE348112T1 AT04724505T AT04724505T ATE348112T1 AT E348112 T1 ATE348112 T1 AT E348112T1 AT 04724505 T AT04724505 T AT 04724505T AT 04724505 T AT04724505 T AT 04724505T AT E348112 T1 ATE348112 T1 AT E348112T1
Authority
AT
Austria
Prior art keywords
cancer
antibodies
modifying antibodies
segregating
staging
Prior art date
Application number
AT04724505T
Other languages
English (en)
Inventor
David S F Young
Susan E Hahn
Original Assignee
Arius Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arius Res Inc filed Critical Arius Res Inc
Application granted granted Critical
Publication of ATE348112T1 publication Critical patent/ATE348112T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04724505T 2003-04-14 2004-03-31 Krebserkrankungen modifizierende antikörper ATE348112T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/413,755 US6794494B1 (en) 2003-04-14 2003-04-14 Cancerous disease modifying antibodies

Publications (1)

Publication Number Publication Date
ATE348112T1 true ATE348112T1 (de) 2007-01-15

Family

ID=32990305

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04724505T ATE348112T1 (de) 2003-04-14 2004-03-31 Krebserkrankungen modifizierende antikörper

Country Status (16)

Country Link
US (1) US6794494B1 (de)
EP (2) EP1613656B1 (de)
JP (1) JP2007523838A (de)
CN (1) CN100588662C (de)
AT (1) ATE348112T1 (de)
AU (1) AU2004228078A1 (de)
CA (1) CA2521375A1 (de)
CY (1) CY1106455T1 (de)
DE (1) DE602004003689T2 (de)
DK (1) DK1613656T3 (de)
ES (1) ES2278309T3 (de)
NZ (1) NZ542927A (de)
PL (1) PL1613656T3 (de)
PT (1) PT1613656E (de)
SI (1) SI1613656T1 (de)
WO (1) WO2004089989A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005351A2 (en) * 2002-07-04 2004-01-15 Oncomab Gmbh Neoplasm specific antibodies and uses thereof
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7195764B2 (en) * 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7348413B2 (en) * 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7494648B2 (en) 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CA2731129A1 (en) * 2008-07-17 2010-01-21 Helen P. Findlay Cancerous disease modifying antibodies
CA2791652C (en) 2010-03-02 2018-06-12 Kyowa Hakko Kirin Co., Ltd. Modified antibody composition
AU2015334886B9 (en) 2014-10-23 2021-07-08 Innate Pharma Treatment of cancers using anti-NKG2A agents
AU2019412489A1 (en) 2018-12-26 2021-06-10 Innate Pharma Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
EP0199141A3 (de) * 1985-04-19 1988-07-20 Sloan-Kettering Institute For Cancer Research Monoklonale Antikörper gegen humanen Magen-Darmkrebs
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5338832A (en) * 1987-07-02 1994-08-16 Akzo N.V. Antigen recognized by MCA 16-88
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
EP0539970B1 (de) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
ATE419355T1 (de) * 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
IL105008A0 (en) 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
WO1994018562A1 (en) 1993-02-05 1994-08-18 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
EP1018518A2 (de) 1994-06-24 2000-07-12 Vladimir P. Torchilin Verwendung von Autoantikörpern zur Tumorbehandlung und Vorbeugung
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6376654B1 (en) * 1999-08-13 2002-04-23 Molecular Discoveries, Llc Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
PT2163256E (pt) * 2001-05-11 2015-11-20 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações

Also Published As

Publication number Publication date
CN1802387A (zh) 2006-07-12
CN100588662C (zh) 2010-02-10
EP1613656B1 (de) 2006-12-13
US6794494B1 (en) 2004-09-21
WO2004089989A1 (en) 2004-10-21
AU2004228078A1 (en) 2004-10-21
CA2521375A1 (en) 2004-10-21
EP1613656A1 (de) 2006-01-11
EP1757620A3 (de) 2007-11-21
ES2278309T3 (es) 2007-08-01
DE602004003689T2 (de) 2007-10-04
SI1613656T1 (sl) 2007-04-30
PT1613656E (pt) 2007-02-28
DK1613656T3 (da) 2007-03-12
PL1613656T3 (pl) 2007-04-30
EP1757620A2 (de) 2007-02-28
CY1106455T1 (el) 2011-10-12
NZ542927A (en) 2008-04-30
JP2007523838A (ja) 2007-08-23
DE602004003689D1 (de) 2007-01-25

Similar Documents

Publication Publication Date Title
EP1718737A4 (de) Antikörper, die krebserkrankungen modifizieren
WO2007095749A8 (en) Cytotoxicity mediation of cells evidencing surface expression of trop-2
CY1106455T1 (el) Τροποποιητικα αντισωματα καρκινικης νοσου
MX2009007619A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2004065422A3 (en) Cancerous disease modifying antibodies
BRPI0601736A (pt) métodos de terapia adjuvante, método de cura de cáncer de mama não metastático, método de redução de reincidência de doenças, método de instrução de pacientes humanos com cáncer de mama her2-positivo não metastático, método de produção e métodos comerciais
MX2009001015A (es) Anticuerpos modificadores de enfermedad cancerosa.
IL146127A0 (en) Conformationally restricted polymine analogs as disease therapies
WO2005012361A3 (en) Antibodies raised against colon carcinomas
MX2009007617A (es) Anticuerpos modificadores de una enfermedad cancerigena.
MX2009007618A (es) Anticuerpos modificadores de una enfermedad cancerigena.
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
CY1108194T1 (el) Μεθοδος παραγωγης κυτταροτοξικων αντικαρκινικων αντισωματων
EP1929034A4 (de) Antikörper, die krebserkrankungen modifizieren
MX2009011667A (es) Anticuerpos de modificacion de enfermedad cancerosa.
MX2009009919A (es) Anticuerpo 010207-01 modificador de la enfermedad del cancer, producido por la linea celular ar51a630.3 del hibridoma.
MX2009001292A (es) Anticuerpos modificadores de enfermedad cancerosa.
WO2008058380A8 (en) Cancerous disease modifying antibodies
NO20091459L (no) Cancerose sykdomsmodifiserende antistoffer
AR070279A1 (es) Anticuerpos modificadores de enfermedades cancerosas (cdma)
BRPI0718609A8 (pt) Anticorpos modificadores de doença cancerosa.
AR072750A1 (es) Anticuerpos modificadores de enfermedades cancerosas
AR070280A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas (cdmab)
AR071847A1 (es) Anticuerpos monoclonales modificadores de enfermedades cancerosas
AR070278A1 (es) Aislamiento y produccion de anticuerpos modificadores de enfermedades cancerosas (cdmab) y uso de los mismos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1613656

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee